Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive ...
Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive ...
Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...
DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the ...
The world’s population is aging at an unprecedented pace. According to WHO’s October 2024 report, the number of people aged 60 and older surpassed children under five for the first time in 2020. By ...
Revenue for Q4 2024 was $1.114 billion, marking an 8% increase year-over-year. Non-GAAP EPS stood at $0.45, missing the estimated $0.50 and reflecting a 10% decline from Q4 2023. Operating income (non ...
Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...
I last covered DexCom (NASDAQ:DXCM) over 1 year ago, when the company's stock price had collapsed from a then all-time peak of $290 to $191, during the market selloff in response to the onset of the ...
This year started with healthy gains for DexCom (NASDAQ: DXCM) stock, but they didn't last long. The medical device stock is now down by about 53% from the high-water mark it set in April. DexCom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback